ATE429221T1 - Medikamente zur behandlung oder prävention fibrotischer krankheiten - Google Patents

Medikamente zur behandlung oder prävention fibrotischer krankheiten

Info

Publication number
ATE429221T1
ATE429221T1 AT05823645T AT05823645T ATE429221T1 AT E429221 T1 ATE429221 T1 AT E429221T1 AT 05823645 T AT05823645 T AT 05823645T AT 05823645 T AT05823645 T AT 05823645T AT E429221 T1 ATE429221 T1 AT E429221T1
Authority
AT
Austria
Prior art keywords
medications
prevention
treatment
fibrotic diseases
fibrotic
Prior art date
Application number
AT05823645T
Other languages
English (en)
Inventor
John Park
Nveed Chaudhary
Thorsten Lehmann-Lintz
Armin Heckel
Gerald Roth
Joerg Kley
Trixi Brandl
Georg Dahmann
Matthias Grauert
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35809691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE429221(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of ATE429221T1 publication Critical patent/ATE429221T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05823645T 2004-12-24 2005-12-21 Medikamente zur behandlung oder prävention fibrotischer krankheiten ATE429221T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04030768 2004-12-24
PCT/EP2005/057006 WO2006067168A1 (en) 2004-12-24 2005-12-21 Medicaments for the treatment or prevention of fibrotic diseases

Publications (1)

Publication Number Publication Date
ATE429221T1 true ATE429221T1 (de) 2009-05-15

Family

ID=35809691

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05823645T ATE429221T1 (de) 2004-12-24 2005-12-21 Medikamente zur behandlung oder prävention fibrotischer krankheiten

Country Status (10)

Country Link
US (2) US20060154939A1 (de)
EP (1) EP1830842B1 (de)
JP (1) JP2008525371A (de)
AR (1) AR052841A1 (de)
AT (1) ATE429221T1 (de)
CA (1) CA2591084A1 (de)
DE (1) DE602005014141D1 (de)
ES (1) ES2326276T3 (de)
TW (1) TW200635595A (de)
WO (1) WO2006067168A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
CA2690569A1 (en) * 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh Indolinone derivatives and their use in treating disease-states such as cancer
UY32010A (es) 2008-07-29 2010-02-26 Boehringer Ingelheim Int Nuevas indolinonas, composiciones conteniéndolas y aplicaciones
US10450295B2 (en) 2013-08-09 2019-10-22 Acclaim BioMed USA LLC Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis
ES2796358T3 (es) * 2015-12-24 2020-11-26 Respivert Ltd Compuestos de indolinonas y su uso en el tratamiento de enfermedades fibróticas
EP3426649B1 (de) * 2016-03-08 2020-07-22 Respivert Limited Indolederivate und ihre verwendung als protein kinase hemmer
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN118252833A (zh) * 2022-12-27 2024-06-28 上海数因信科智能科技有限公司 Vofopitant用于治疗肺纤维化的用途
CN118252832A (zh) * 2022-12-27 2024-06-28 上海数因信科智能科技有限公司 Vofopitant用于治疗硬皮病的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043254A (en) * 1998-04-03 2000-03-28 Boehringer Ingelheim Pharma Kg Indolinones having kinase-inhibiting activity
US6169106B1 (en) * 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
US6319918B1 (en) * 1998-06-04 2001-11-20 Boehringer Ingelheim Pharma Kg Substituted indolinones with kinase inhibitory activity
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
EP1311277A4 (de) * 2000-07-18 2004-08-25 Joslin Diabetes Center Inc Methoden zur fibrose-modulation
DE10117204A1 (de) * 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas

Also Published As

Publication number Publication date
EP1830842A1 (de) 2007-09-12
AR052841A1 (es) 2007-04-04
US20060154939A1 (en) 2006-07-13
TW200635595A (en) 2006-10-16
ES2326276T3 (es) 2009-10-06
DE602005014141D1 (de) 2009-06-04
WO2006067168A1 (en) 2006-06-29
CA2591084A1 (en) 2006-06-29
JP2008525371A (ja) 2008-07-17
EP1830842B1 (de) 2009-04-22
US20090048267A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
SI2878297T1 (sl) Zdravila za zdravljenje ali preprečevanje fibroznih bolezni
EP1759710A4 (de) Mittel zur behandlung oder prävention von arthritis
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
EP1851237A4 (de) Pharmazeutische zusammensetzungen zur behandlung oder prävention von knochenerkrankungen
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
HUS1500058I1 (hu) Benzoxazint tartalmazó gyógyszer-kombináció légúti betegségek kezelésére
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
EP1905452A4 (de) Wirkstoff zur prävention oder behandlung von glaukomen
ATE429221T1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
ATE359270T1 (de) Phenyl-piperidin-4-yliden-methyl-benzamidderiva e zur behandlung von schmerz oder magen-darm- erkrankungen
DE602006010364D1 (de) Pharmazeutikum zur prävention oder behandlung von metabolischer knochenkrankheit
ATE446757T1 (de) 1-ä2h-1-benzopyran-2-one-8-ylü- piperazinderivative zur behandlung von bewegungsstörungen
DE602005014624D1 (de) Verbindungen zur behandlung von krankheiten
DE602005023842D1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
GB0407710D0 (en) Treatment of diseases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1830842

Country of ref document: EP

REN Ceased due to non-payment of the annual fee